PMID- 17201810
OWN - NLM
STAT- MEDLINE
DCOM- 20070723
LR  - 20071115
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 66
IP  - 1
DP  - 2007 Jan
TI  - Co-expression of ghrelin and its receptor in pancreatic endocrine tumours.
PG  - 115-22
AB  - OBJECTIVE: Expression of ghrelin has been reported in pancreatic endocrine 
      tumours, but data on ghrelin receptor protein expression are lacking. The aim of 
      this study was to examine the ghrelin receptor, as well as ghrelin, in a selected 
      series of these tumours, including multiple endocrine neoplasia 1 (MEN1) 
      associated tumours, and to correlate data with clinical features including body 
      mass index. DESIGN: Immunohistochemical detection of ghrelin and its receptor was 
      performed on frozen tissue from 31 tumours: 9 MEN1 and 22 sporadic. Twenty 
      tumours were analysed by quantitative PCR. Plasma ghrelin was assessed in 26 
      patients. RESULTS: Twenty-one (68%) of 31 tumours showed immunoreactivity for 
      ghrelin (8/9 MEN1) and 19/20 expressed ghrelin mRNA. Ghrelin receptor protein was 
      detected in 21/30 (70%) tumours (4/8 MEN1), and mRNA was detected in all analysed 
      tumours. Insulinomas had significantly higher levels of receptor mRNA than other 
      tumours. Five patients had elevated plasma ghrelin (> 2 SD above the control 
      group mean). No significant difference in mean plasma ghrelin levels was found 
      between patients (908 +/- 569 ng/l) and controls (952 +/- 164 ng/l). Mean BMI was 
      24.3 kg/m(2). There was no association between ghrelin or receptor expression and 
      survival. CONCLUSIONS: We report the first immunohistochemical data on expression 
      of the ghrelin receptor in pancreatic endocrine tumours: 70% of tumours in our 
      material. Concomitant ghrelin and receptor expression was seen in 50% of tumours, 
      indicating an autocrine loop. Ghrelin was expressed in 68% of tumours (8/9 MEN1). 
      Despite frequent ghrelin expression, elevated circulating ghrelin is rare in 
      these patients.
FAU - Ekeblad, Sara
AU  - Ekeblad S
AD  - Department of Medical Sciences, University Hospitals, Uppsala, Sweden.
FAU - Lejonklou, Margareta Halin
AU  - Lejonklou MH
FAU - Grimfjard, Per
AU  - Grimfjard P
FAU - Johansson, Terese
AU  - Johansson T
FAU - Eriksson, Barbro
AU  - Eriksson B
FAU - Grimelius, Lars
AU  - Grimelius L
FAU - Stridsberg, Mats
AU  - Stridsberg M
FAU - Stalberg, Peter
AU  - Stalberg P
FAU - Skogseid, Britt
AU  - Skogseid B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Ghrelin)
RN  - 0 (Peptide Hormones)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Receptors, Ghrelin)
SB  - IM
MH  - Adenoma, Islet Cell/blood/chemistry/*metabolism
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Body Mass Index
MH  - Chi-Square Distribution
MH  - Female
MH  - Gene Expression
MH  - Ghrelin
MH  - Humans
MH  - Immunohistochemistry
MH  - Insulinoma/chemistry/metabolism
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/chemistry/metabolism
MH  - Pancreatic Neoplasms/blood/chemistry/*metabolism
MH  - Peptide Hormones/analysis/blood/*genetics
MH  - Receptors, G-Protein-Coupled/analysis/*genetics
MH  - Receptors, Ghrelin
MH  - Survival Rate
EDAT- 2007/01/05 09:00
MHDA- 2007/07/24 09:00
CRDT- 2007/01/05 09:00
PHST- 2007/01/05 09:00 [pubmed]
PHST- 2007/07/24 09:00 [medline]
PHST- 2007/01/05 09:00 [entrez]
AID - CEN2695 [pii]
AID - 10.1111/j.1365-2265.2006.02695.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2007 Jan;66(1):115-22. doi: 
      10.1111/j.1365-2265.2006.02695.x.